Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
???displayArticle.abstract???
DNA interstrand crosslinks (ICLs) are cytotoxic lesions that covalently link opposite strands of the DNA helix and block DNA unwinding. ICLs are repaired during and outside S phase, and replication-independent ICL repair (RIR) is critical to maintain genomic integrity and to allow transcription in nondividing or slowly dividing cells. Here, we show that the Y family DNA polymerase kappa (Pol κ) is essential for RIR of a site-specific ICL lesion in Xenopus egg extracts, and that both its catalytic activity and UBZ domains are required for this function. We also demonstrate a requirement for PCNA and its modification on lysine 164. Finally, we show that Pol κ participates in ICL repair in mammalian cells, particularly in G0. Our results identify key components of the RIR pathway and begin to unravel its mechanism.
Figure 1. Replication-Independent ICL Repair Occurs via a Mechanism that Is Distinct from Replication-Dependent ICL Repair
(A) Schematic representation of the ICL plasmid. Regions amplified by the X and C primers are illustrated.
(B) ICL plasmid was incubated in HSS (nonreplicating) or HSS + NPE (replication-competent) extract for the times indicated. Repair (%) is measured as the fraction of the X:C ratio of the ICL plasmid over the X:C ratio of the control plasmid. See also Figure S1.
(C) Quantification of ICL repair in mock- and FANCI-depleted HSS or in HSS treated with 100 μM curcumin.
(D) Quantification of ICL repair in mock- and Rad51-depleted HSS.
(E) Quantification of ICL repair in mock- and Rev7-depleted HSS. Results represent the mean and SEM from at least three independent experiments.
Figure 2. Pol κ Is Required for RIR
(A) ICL repair in mock-, Pol κ-, and Pol κ-depleted HSS supplemented with recombinant Pol κWT or Pol κD199A, E200A. See also Figure S2.
(B) Schematic showing the domain structure of Pol κ and the location of mutations used in this study. Asterisks mark the location of the mutations shown in bold and underlined in the table below.
(C) Quantification of ICL repair in mock-depleted HSS, Pol κ-depleted HSS, and Pol κ-depleted HSS supplemented with recombinant Pol κF562A, F563A.
(D) ICL and control plasmids were incubated in Pol κ-depleted HSS, supplemented with either Pol κWT or Pol κD199A, E200A and anaylzed by Pol κ ChIP. The data are expressed as the fold enrichment of DNA pulled down from ICL plasmid compared to control plasmid. A value of 1 (dashed line) indicates no enrichment. Results represent the mean and SEM from at least three independent experiments.
Figure 3. PCNA Modification on Lysine 164 and Pol κ UBZ Domains Are Required for RIR
(A) Quantification of ICL repair in mock- and Rad1-depleted HSS. See also Figure S3.
(B) Quantification of ICL repair in mock-depleted HSS, PCNA-depleted HSS, and PCNA-depleted HSS supplemented with PCNAWT or PCNAK164R.
(C) Control or ICL plasmids were incubated in extract for 40 min and immobilized using biotinylated LacR protein. DNA-bound proteins were analyzed by western blotting.
(D) Quantification of ICL repair in mock-, Pol κ-, or Pol κ-depleted HSS supplemented with Pol κWT, Pol κD634A,D789A, or Pol κI857A,F860A,F861A, as indicated. Results represent the mean and SEM from at least three independent experiments.
Figure 4. Pol κ−/− MEF Sensitivity to Crosslinking Agents Correlates with a Defect in ICL Repair
(A) Schematic of GFP-based ICL assay.
(B) Quantification of the repair of a single site-specific ICL in either Pol κ−/− or Pol κ+/+ MEFs using the GFP-based assay shown in (A). Repair is expressed as the fraction of GFP-positive cells transfected with the ICL plasmid over GFP-positive cells transfected with the control plasmid.
(C) Clonogenic survival assays with Pol κ−/− or Pol κ+/+ MEFs in the presence of the indicated concentration of MMC. Cells were treated during exponential growth or during G0 arrest.
(D) Clonogenic survival assay with Pol κ−/− or Pol κ+/+ MEFs in the presence of the indicated concentration of cisplatin during exponential growth. Results represent the mean and SEM from at least three independent experiments.
Acharya,
DNA polymerase eta lacking the ubiquitin-binding domain promotes replicative lesion bypass in humans cells.
2010, Pubmed
Acharya,
DNA polymerase eta lacking the ubiquitin-binding domain promotes replicative lesion bypass in humans cells.
2010,
Pubmed Ben-Yehoyada,
Checkpoint signaling from a single DNA interstrand crosslink.
2009,
Pubmed
,
Xenbase Bi,
Rad18 regulates DNA polymerase kappa and is required for recovery from S-phase checkpoint-mediated arrest.
2006,
Pubmed Chirnomas,
Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway.
2006,
Pubmed Ciccia,
Identification of FAAP24, a Fanconi anemia core complex protein that interacts with FANCM.
2007,
Pubmed Deans,
DNA interstrand crosslink repair and cancer.
2011,
Pubmed Deans,
FANCM connects the genome instability disorders Bloom's Syndrome and Fanconi Anemia.
2009,
Pubmed Dooley,
NMR determination of the conformation of a trimethylene interstrand cross-link in an oligodeoxynucleotide duplex containing a 5'-d(GpC) motif.
2003,
Pubmed D'Souza,
Novel role for the C terminus of Saccharomyces cerevisiae Rev1 in mediating protein-protein interactions.
2006,
Pubmed Gerlach,
Purification and characterization of pol kappa, a DNA polymerase encoded by the human DINB1 gene.
2001,
Pubmed Guo,
Mouse Rev1 protein interacts with multiple DNA polymerases involved in translesion DNA synthesis.
2003,
Pubmed Guo,
Requirements for the interaction of mouse Polkappa with ubiquitin and its biological significance.
2008,
Pubmed Haracska,
Physical and functional interactions of human DNA polymerase eta with PCNA.
2001,
Pubmed Hishiki,
Structural basis for novel interactions between human translesion synthesis polymerases and proliferating cell nuclear antigen.
2009,
Pubmed Hlavin,
Initiation of DNA interstrand cross-link repair in mammalian cells.
2010,
Pubmed Ho,
Translesion DNA synthesis polymerases in DNA interstrand crosslink repair.
2010,
Pubmed Ho,
Structure-dependent bypass of DNA interstrand crosslinks by translesion synthesis polymerases.
2011,
Pubmed Kai,
Checkpoint activation regulates mutagenic translesion synthesis.
2003,
Pubmed Kelman,
Protein-PCNA interactions: a DNA-scanning mechanism?
1998,
Pubmed Knipscheer,
The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair.
2009,
Pubmed
,
Xenbase Lebofsky,
DNA replication in nucleus-free Xenopus egg extracts.
2009,
Pubmed
,
Xenbase Lehmann,
Translesion synthesis in mammalian cells.
2006,
Pubmed Long,
Mechanism of RAD51-dependent DNA interstrand cross-link repair.
2011,
Pubmed
,
Xenbase Lupardus,
A requirement for replication in activation of the ATR-dependent DNA damage checkpoint.
2002,
Pubmed
,
Xenbase Mattock,
Use of peptides from p21 (Waf1/Cip1) to investigate PCNA function in Xenopus egg extracts.
2001,
Pubmed
,
Xenbase Minko,
Role for DNA polymerase kappa in the processing of N2-N2-guanine interstrand cross-links.
2008,
Pubmed Moldovan,
PCNA, the maestro of the replication fork.
2007,
Pubmed Moore,
Quiescent, slow-cycling stem cell populations in cancer: a review of the evidence and discussion of significance.
2011,
Pubmed Mu,
DNA interstrand cross-links induce futile repair synthesis in mammalian cell extracts.
2000,
Pubmed Ogi,
Mutation enhancement by DINB1, a mammalian homologue of the Escherichia coli mutagenesis protein dinB.
1999,
Pubmed Ogi,
Localisation of human Y-family DNA polymerase kappa: relationship to PCNA foci.
2005,
Pubmed Ogi,
Three DNA polymerases, recruited by different mechanisms, carry out NER repair synthesis in human cells.
2010,
Pubmed Ogi,
Polkappa protects mammalian cells against the lethal and mutagenic effects of benzo[a]pyrene.
2002,
Pubmed Ogi,
The Y-family DNA polymerase kappa (pol kappa) functions in mammalian nucleotide-excision repair.
2006,
Pubmed Ohashi,
Fidelity and processivity of DNA synthesis by DNA polymerase kappa, the product of the human DINB1 gene.
2000,
Pubmed Ohashi,
Identification of a novel REV1-interacting motif necessary for DNA polymerase kappa function.
2009,
Pubmed Ohashi,
Interaction of hREV1 with three human Y-family DNA polymerases.
2004,
Pubmed Räschle,
Mechanism of replication-coupled DNA interstrand crosslink repair.
2008,
Pubmed
,
Xenbase Sarkar,
DNA interstrand crosslink repair during G1 involves nucleotide excision repair and DNA polymerase zeta.
2006,
Pubmed Schenten,
DNA polymerase kappa deficiency does not affect somatic hypermutation in mice.
2002,
Pubmed Sengerová,
Orchestrating the nucleases involved in DNA interstrand cross-link (ICL) repair.
2011,
Pubmed Shechter,
ATR and ATM regulate the timing of DNA replication origin firing.
2004,
Pubmed
,
Xenbase Shimizu,
Normal immunoglobulin gene somatic hypermutation in Pol kappa-Pol iota double-deficient mice.
2005,
Pubmed Smeaton,
Effect of cross-link structure on DNA interstrand cross-link repair synthesis.
2009,
Pubmed Smeaton,
Distortion-dependent unhooking of interstrand cross-links in mammalian cell extracts.
2008,
Pubmed Smogorzewska,
Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair.
2007,
Pubmed Takenaka,
Involvement of vertebrate Polkappa in translesion DNA synthesis across DNA monoalkylation damage.
2006,
Pubmed Toledo,
A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations.
2011,
Pubmed Ulrich,
The RAD6 pathway: control of DNA damage bypass and mutagenesis by ubiquitin and SUMO.
2005,
Pubmed Vidal,
Proliferating cell nuclear antigen-dependent coordination of the biological functions of human DNA polymerase iota.
2004,
Pubmed Walter,
Regulation of replicon size in Xenopus egg extracts.
1997,
Pubmed
,
Xenbase Waters,
Eukaryotic translesion polymerases and their roles and regulation in DNA damage tolerance.
2009,
Pubmed
